Literature DB >> 15134540

Aryloxy phosphoramidate triesters as pro-tides.

Dominique Cahard1, Christopher McGuigan, Jan Balzarini.   

Abstract

We herein describe the development of aryloxy phosphoramidate triesters as an effective pro-tide motif for the intracellular delivery of charged bio-active antiviral nucleoside monophosphates. The review covers the discovery of such aryl phosphoramidates, their mechanism of action and structure-activity relationships. The application of this strategy to a range of antiviral nucleosides is highlighted.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15134540     DOI： 10.2174/1389557043403936

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN： 1389-5575            Impact factor:   3.862


  41 in total

1.  Thiophene-expanded guanosine analogues of Gemcitabine.

Authors:  Zhe Chen; Therese C Ku; Katherine L Seley-Radtke
Journal:  Bioorg Med Chem Lett       Date:  2015-07-30       Impact factor: 2.823

2.  Adenosine Dioxolane Nucleoside Phosphoramidates as Antiviral Agents for Human Immunodeficiency and Hepatitis B Viruses.

Authors:  Lavanya Bondada; Mervi Detorio; Leda Bassit; Sijia Tao; Catherine M Montero; Tyana M Singletary; Hongwang Zhang; Longhu Zhou; Jong-Hyun Cho; Steven J Coats; Raymond F Schinazi
Journal:  ACS Med Chem Lett       Date:  2013-08-08       Impact factor: 4.345

Review 3.  Advances in nucleoside monophosphate prodrugs as anti-HCV agents.

Authors:  Drew R Bobeck; Raymond F Schinazi; Steven J Coats
Journal:  Antivir Ther       Date:  2010

4.  Anti-hepatitis C virus activity of novel beta-d-2'-C-methyl-4'-azido pyrimidine nucleoside phosphoramidate prodrugs.

Authors:  Ramu Rondla; Steven J Coats; Tamara R McBrayer; Jason Grier; Melissa Johns; Phillip M Tharnish; Tony Whitaker; Longhu Zhou; Raymond F Schinazi
Journal:  Antivir Chem Chemother       Date:  2009-10-19

5.  INX-08189, a phosphoramidate prodrug of 6-O-methyl-2'-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties.

Authors:  John H Vernachio; Blair Bleiman; K Dawn Bryant; Stanley Chamberlain; Damound Hunley; Jeff Hutchins; Brenda Ames; Elena Gorovits; Babita Ganguly; Andrea Hall; Alexander Kolykhalov; Yule Liu; Jerry Muhammad; Nicholas Raja; C Robin Walters; Jin Wang; Karen Williams; Joseph M Patti; Geoffrey Henson; Karolina Madela; Mohamed Aljarah; Arnaud Gilles; Christopher McGuigan
Journal:  Antimicrob Agents Chemother       Date:  2011-02-28       Impact factor: 5.191

Review 6.  Synthesis of nucleoside phosphate and phosphonate prodrugs.

Authors:  Ugo Pradere; Ethel C Garnier-Amblard; Steven J Coats; Franck Amblard; Raymond F Schinazi
Journal:  Chem Rev       Date:  2014-08-21       Impact factor: 60.622

7.  Development and Validation of a Phenotypic High-Content Imaging Assay for Assessing the Antiviral Activity of Small-Molecule Inhibitors Targeting Zika Virus.

Authors:  Jean A Bernatchez; Zunhua Yang; Michael Coste; Jerry Li; Sungjun Beck; Yan Liu; Alex E Clark; Zhe Zhu; Lucas A Luna; Christal D Sohl; Byron W Purse; Rongshi Li; Jair L Siqueira-Neto
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

8.  A new class of dual-targeted antivirals: monophosphorylated acyclovir prodrug derivatives suppress both human immunodeficiency virus type 1 and herpes simplex virus type 2.

Authors:  Christophe Vanpouille; Andrea Lisco; Marco Derudas; Elisa Saba; Jean-Charles Grivel; Beda Brichacek; Francesca Scrimieri; Raymond Schinazi; Dominique Schols; Christopher McGuigan; Jan Balzarini; Leonid Margolis
Journal:  J Infect Dis       Date:  2010-02-15       Impact factor: 5.226

Review 9.  Prodrug approaches to improving the oral absorption of antiviral nucleotide analogues.

Authors:  Larryn W Peterson; Charles E McKenna
Journal:  Expert Opin Drug Deliv       Date:  2009-04       Impact factor: 6.648

10.  Evolution of an amino acid based prodrug approach: stay tuned.

Authors:  Ivan S Krylov; Boris A Kashemirov; John M Hilfinger; Charles E McKenna
Journal:  Mol Pharm       Date:  2013-01-22       Impact factor: 4.939
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.